KI-100X

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameKI-100X
Drug Alias Nameintegrin alphaVbeta3-targeted chemotherapy (Kereos)integrin alphaVbeta3-targeted nanoparticles (Kereos)KI-100XKI-1001
ClassificationRadiation-emitting products > Radioactive therapeutic agentDiagnostic agent (In vivo)
Mechanisms of ActionIntegrin alpha-V/beta-3 modulatorsAngiogenesis inhibitors
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesKereos Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKereos Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A